Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
reFOQus: Real World Study of FOQUEST vs VYVANSE in ADHD
NCT04152629Phase 4Completed
- Sponsor
- Purdue Pharma
- Start
- Sep 2019
- Primary completion
- Jul 2021
- Modality
- Small Molecules, Implantable Devices
- Countries
- 1
01
Overview
Phase 4, open-label trial of Adhansia XR in attention deficit hyperactivity disorder (ADHD) (4 arms), sponsored by Purdue Pharma. Primary endpoint: ADHD Rating Scale Total Score at 4 months. Started Sep 2019; status: completed.
02
Drugs
Adhansia XR
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT04152629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04152629.